PATENT CLAIM ANALYSIS

Application Number: 15977968
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "130100"]

Abstract:
Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Claim (Index 12):
The single domain mesothelin binding protein of  claim 9 , wherein said protein comprises the following formula:\n f1-r1-f2-r2-f3-r3-f4 wherein, r1 CDR1; r2 is CDR2; and r3 CDR3; and wherein f1, f2, f3 and f4 are framework residues.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 93.0
- Lexical Diversity: 1.26471
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15141463', '15866222', '15368278', '15105082', '14428771']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.77710497773041
- 35 USC 102 Novelty (BERT): 0.5454055624491352
- Combined Prediction Score: 0.7539350362022825
- Mean Citation Score: 360.573688
- Max Citation Score: 411.167
- Similarity Product: 280.45700987654925

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test